MDT

96.24

+0.35%↑

VEEV

285.71

-0.58%↓

A

138.04

-0.83%↓

HQY

94.48

+2.41%↑

PHR.US

22.63

+2.72%↑

MDT

96.24

+0.35%↑

VEEV

285.71

-0.58%↓

A

138.04

-0.83%↓

HQY

94.48

+2.41%↑

PHR.US

22.63

+2.72%↑

MDT

96.24

+0.35%↑

VEEV

285.71

-0.58%↓

A

138.04

-0.83%↓

HQY

94.48

+2.41%↑

PHR.US

22.63

+2.72%↑

MDT

96.24

+0.35%↑

VEEV

285.71

-0.58%↓

A

138.04

-0.83%↓

HQY

94.48

+2.41%↑

PHR.US

22.63

+2.72%↑

MDT

96.24

+0.35%↑

VEEV

285.71

-0.58%↓

A

138.04

-0.83%↓

HQY

94.48

+2.41%↑

PHR.US

22.63

+2.72%↑

Search

Cerus Corp

Open

BrancheGesundheitswesen

1.53 -2.55

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.49

Max

1.57

Schlüsselkennzahlen

By Trading Economics

Einkommen

2M

-5.7M

Verkäufe

9.2M

52M

Gewinnspanne

-10.897

Angestellte

614

EBITDA

2.7M

-3.1M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+118.75% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

29. Okt. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

60M

309M

Vorheriger Eröffnungskurs

4.08

Vorheriger Schlusskurs

1.53

Nachrichtenstimmung

By Acuity

67%

33%

346 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Cerus Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Okt. 2025, 21:45 UTC

Akquisitionen, Fusionen, Übernahmen

Goldman Sachs to Acquire Industry Ventures for Up to $965 Million -- Update

13. Okt. 2025, 21:07 UTC

Akquisitionen, Fusionen, Übernahmen

Goldman Sachs to Acquire Industry Ventures for Up to $965 Million

13. Okt. 2025, 17:03 UTC

Wichtige Markttreiber

Canaan ADRs Climb on Launch of Gas-to-Computing Pilot in Canada

13. Okt. 2025, 23:53 UTC

Market Talk

Gold Rises, Buoyed by Bullish Fundamental Backdrop -- Market Talk

13. Okt. 2025, 23:39 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

13. Okt. 2025, 22:15 UTC

Market Talk

Global Equities Roundup: Market Talk

13. Okt. 2025, 22:15 UTC

Market Talk

Precinct Properties NZ's Equity Raising Looks Opportunistic -- Market Talk

13. Okt. 2025, 21:57 UTC

Akquisitionen, Fusionen, Übernahmen

Goldman Buys $7B Venture-Capital Firm in Latest Asset-Management Bet -- Barrons.com

13. Okt. 2025, 21:36 UTC

Market Talk

Global Equities Roundup: Market Talk

13. Okt. 2025, 21:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13. Okt. 2025, 21:36 UTC

Market Talk

Fletcher's Near-Term Headwinds Don't Cloud Earnings Opportunity -- Market Talk

13. Okt. 2025, 21:30 UTC

Akquisitionen, Fusionen, Übernahmen

Goldman Sachs to Acquire Industry Ventures for Up to $965M -- Update

13. Okt. 2025, 21:06 UTC

Akquisitionen, Fusionen, Übernahmen

Goldman Buys $7B Venture-Capital Firm in Latest Asset-Management Bet -- Barrons.com

13. Okt. 2025, 20:52 UTC

Akquisitionen, Fusionen, Übernahmen

Goldman Sachs to Acquire Industry Ventures for Up to $965M

13. Okt. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

13. Okt. 2025, 20:35 UTC

Akquisitionen, Fusionen, Übernahmen

Goldman Expects to Close Deal in 1Q

13. Okt. 2025, 20:34 UTC

Akquisitionen, Fusionen, Übernahmen

Industry Ventures Will Be Part of Goldman's External Manager Platform, External Investing Group

13. Okt. 2025, 20:33 UTC

Akquisitionen, Fusionen, Übernahmen

Industry Ventures Currently Manages $7B of Assets Under Supervision

13. Okt. 2025, 20:32 UTC

Akquisitionen, Fusionen, Übernahmen

Goldman Sachs: Deal to Include Up to $300M of Additional Contingent Consideration Based on Future Performance Through 2030

13. Okt. 2025, 20:31 UTC

Akquisitionen, Fusionen, Übernahmen

Goldman Sachs: Consideration to Include $665M Cash and Equity Payable at Closing

13. Okt. 2025, 20:29 UTC

Akquisitionen, Fusionen, Übernahmen

Goldman Sachs to Buy VC Firm Industry Ventures

13. Okt. 2025, 19:05 UTC

Market Talk

Oil Futures Pick Up on Easing U.S.-China Tension -- Market Talk

13. Okt. 2025, 18:59 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

13. Okt. 2025, 18:26 UTC

Market Talk

Precious Metals Close at New Record Highs -- Market Talk

13. Okt. 2025, 18:10 UTC

Market Talk

Global Equities Roundup: Market Talk

13. Okt. 2025, 18:10 UTC

Market Talk

Broadcom's OpenAI Deal Highlights AI Opportunity -- Market Talk

13. Okt. 2025, 17:05 UTC

Market Talk

Global Equities Roundup: Market Talk

13. Okt. 2025, 17:05 UTC

Market Talk

OpenAI Deal Offers Huge Upside to Broadcom's Earnings -- Market Talk

13. Okt. 2025, 16:03 UTC

Akquisitionen, Fusionen, Übernahmen

Umicore Completes Sale, Subsequent Lease-in of Permanent Gold Inventories

13. Okt. 2025, 15:35 UTC

Market Talk

Precious Metals Push Record Highs Further -- Market Talk

Peer-Vergleich

Kursveränderung

Cerus Corp Prognose

Kursziel

By TipRanks

118.75% Vorteil

12-Monats-Prognose

Durchschnitt 3.5 USD  118.75%

Hoch 5 USD

Tief 1.5 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cerus Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

5 ratings

3

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

1.3 / 1.36Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

346 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Cerus Corp

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
help-icon Live chat